Contact information
Type
Scientific
Primary contact
Mr Adam Magos
ORCID ID
Contact details
Consultant Gynaecologist
Royal Free Hospital
Pond Street
Hampstead
London
NW3 2QG
United Kingdom
+44 (0)20 7321 1321
a.magos@medsch.ucl.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N0256159688
Study information
Scientific title
Acronym
Study hypothesis
Please note that as of 15/09/2008 this trial has been extensively updated. All updates can be found in the relevant field under the above update date. Please also note that the anticipated start and end dates of this trial have also changed. The previous anticipated trial dates are as follows:
Anticipated start date: 01/09/2004
Anticipated end date: 30/09/2006
Finally, please note that the contact details below have changed since the initial assignation of an ISRCTN. The previous contact for this trial was Dr Lynne Chapman at the Royal Free Hampstead NHS Trust.
Current hypothesis as of 15/09/2008:
Fibroids are common benign tumours of the smooth muscle of the uterus. Historically, an open myomectomy or a hysterectomy has been the mainstay of treatment for symptomatic fibroids. Intra-operative haemorrhage is the most feared complication of myomectomy, necessitating blood transfusion or worse, hysterectomy. Several interventions to reduce intra-operative blood loss at myomectomy have been described, including gonadotropin releasing hormone (GnRH) analogues and intra-operative application of triple tourniquets to occlude the uterine blood supply.
GnRH analogues have been used for a long time to shrink fibroids and reduce blood loss. However, these agents are expensive, they need to be taken for several months prior to surgery in order to exert a noticeable effect, they cause unwanted oestrogen deficient symptoms, and because of their tissue effects, they tend to prolong the surgery.
The use of tourniquets to reduce intra-operative blood loss at open myomectomy is well established. A recent randomised controlled trial from our unit confirmed that triple tourniquets applied to the uterine and ovarian vessels significantly reduced operative blood loss, the need for blood transfusion and peri-operative morbidity at open myomectomy compared with controls. We propose to conduct a randomised controlled trial to compare the efficacy of gonadotropin-releasing hormone (GnRH) analogues and triple tourniquets in reducing intra-operative bleeding compared at open and laparoscopic myomectomy.
Initial hypothesis:
Does the application of surgical tourniquets around the major blood supply to the uterus reduce bleeding, thereby need the blood transfusion compared with traditional GnRH analogues?
Ethics approval
Added 15/09/2008:
Ethics approval received from the Royal Free Hospital & Medical School Local Research and Ethics Committee on the 26th October 2004 (ref: 04/Q0501/94)
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Fibroids
Intervention
Current interventions as of 15/09/2008:
Patients with symptomatic fibroids requiring open myomectomy will be randomised to treatment with either GnRH analogues pre-operatively for 3 months or intra-operative triple tourniquets.
Pre-randomisation assessment:
Each patient will be identified after history, clinical examination and diagnosis are confirmed by means of imaging techniques. Baseline haemoglobin and follicular stimulating hormone (FSH) will also be estimated.
Treatment:
1. GnRH analogues group: pre-operatively treatment (typically using Nafarelin nasal spray 200 µg twice daily [b.d.] or Zoladex 3.6 mg by intramuscular injection every 28 days) will be administered during the 3 months period prior to surgery.
2. Tourniquet group: these patients will have a tourniquet tied around the infundibulo-pelvic ligaments (thus occluding the ovarian vessels on each side) and a number 1 vicryl suture tied around the cervix to occlude the uterine vessels. The tourniquets around the infundibulo-pelvic ligaments will be removed as soon as the uterus has been repaired following the myomectomy, but the suture around the uterine arteries will be left in situ to be gradually absorbed.
Intra-operative assessment:
Operative blood loss will be measured by weighing all swabs and measuring blood collected by suction.
Post-operative follow-up:
In the immediate post-operative period the amount of blood collected in the pelvic drain will be recorded; the drain will stay in situ for a minimum of 48 hours, and will be removed once the drainage is less than 100 ml in 24 hours. Temperature will be monitored in the usual way every 4 - 6 hours. Haemoglobin (Hb) will be measured on day 2; blood transfusion will be given if Hb is less than 8 g/dl or if it is clinically indicated for other reasons. Prior to discharge from hospital patients will undergo doppler studies of uterine blood flow.
Patients will be reviewed at six weeks, three months and six months after surgery. Symptomatic response to the surgery will be documented together with any complications encountered (including menopausal symptoms). Serum FSH levels will also be checked. Patients undergoing laparoscopic myomectomy will be randomised in the operating theatre to one of two groups (with or without triple tourniquets). Pre-operative assessment, intra-operative assessment and technique of applying the tourniquets as well as the post-operative care will be exactly as in the case of open myomectomy (as above).
Initial interventions:
Each patient will be identified. History clinical examination and pelvic. Control group: These patients will be having a standard laparoscopic or open myomectomy (depending on size of fibroids) having several GnRH analogues for 3 months first.
Intervention type
Drug
Phase
Not Specified
Drug names
Gonadotropin releasing hormone (GnRH) analogues
Primary outcome measures
Current primary outcome measures as of 15/09/2008:
Intra-operative blood loss, assessed by the standard method of meticulous measurement of blood loss during surgery, measured at conclusion of surgery.
Initial primary outcome measures:
1. Post-operative blood loss + FPC need for blood transfusion
2. Febrile mortality
3. Ovarian function
4. Uterine blood flow
5. General health
6. Menstrual blood loss
Secondary outcome measures
Added as of 15/09/2008:
1. Post-operative blood loss, assessed by amount collected in surgical drains and by post-operative changes in haemoglobin, measured after removing the drain, i.e. on average this will be at day 2 post-operatively
2. Intra- and post-operative blood transfusion rates. Blood transfusion rate is measured (if it is required) intra-operatively plus (if required) post-operatively.
3. Intra- and post-operative morbidity: immediate post-operative morbidity measured within the first week after surgery. Late morbidity (complications) measured at post- operative check-up at 6 weeks, then 3 months and then 6 months.
4. Ovarian function, assessed by serial serum FSH concentrations: measured pre-operatively and again at follow-up at 6 weeks, then 3 months and then 6 months
Overall trial start date
01/11/2004
Overall trial end date
01/11/2009
Reason abandoned
Eligibility
Participant inclusion criteria
Current inclusion criteria as of 15/09/2008:
Inclusion criteria for open myomectomy:
1. Symptomatic multiple fibroids (more than three fibroids)
2. Uterine size less than 24 weeks gestation equivalent
Inclusion criteria for laparoscopic myomectomy:
1. Uterine size up to 16 - 18 weeks gestation equivalent
2. No more than three fibroids, with maximum diameter of 15 cm 3. Mostly intramural fibroids
Initial inclusion criteria:
Patients will be referred from the GP to our fibroid clinic and have symptomatic fibroids. They will have chosen to have a myomectomy and agreed to be in the study.
Participant type
Patient
Age group
Adult
Gender
Female
Target number of participants
Added as of 15/09/2008: 100 patients
Participant exclusion criteria
Added as of 15/09/2008:
Exclusion criteria for open myomectomy:
1. Large uterus more than 24 weeks gestation equivalent
2. Women with a bleeding disorder
3. Women on anticoagulants
4. Treatment with GnRH analogues within the previous six months
5. Women with a haemoglobin level of less than 10.5 g/dl
Exclusion criteria for laparoscopic myomectomy:
1. Uterine size of more than 16 - 18 weeks gestation equivalent
2. Women with a bleeding disorder
3. Women on anticoagulants
4. Women with a haemoglobin level of less than 10.5 g/dl
5. Mostly subserous fibroids
Recruitment start date
01/11/2004
Recruitment end date
01/11/2009
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Consultant Gynaecologist
London
NW3 2QG
United Kingdom
Sponsor information
Organisation
Department of Health
Sponsor details
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk
Sponsor type
Government
Website
Funders
Funder type
Government
Funder name
The Royal Free Hampstead NHS Trust (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
NHS R&D Support Funding
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
1. 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19191779
Publication citations
-
Results
Al-Shabibi N, Chapman L, Madari S, Papadimitriou A, Papalampros P, Magos A, Prospective randomised trial comparing gonadotrophin-releasing hormone analogues with triple tourniquets at open myomectomy., BJOG, 2009, 116, 5, 681-687, doi: 10.1111/j.1471-0528.2008.02022.x.